Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL8071601 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD11B1CES2CES1MAPT | |
| SCHEMBL11035602 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD11B1CES2CES1MAPT | |
| SCHEMBL61560 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD11B1CES2CES1MAPT | |
| SCHEMBL5201533 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD11B1CES2CES1MAPT | |
| Biphenyl SCHEMBL15309189 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD11B1CES2CES1MAPT | |
| Biphenyl SCHEMBL8160471 | 0.97 | ALDH1A1 (0.50) | ALDH1A1HSD11B1CES2CES1MAPT | |
| Biphenyl SCHEMBL709232 | 0.97 | ALDH1A1 (0.50) | ALDH1A1HSD11B1CES2CES1MAPT | |
| SCHEMBL21463233 | 0.97 | ALDH1A1 (0.57) | ALDH1A1 | |
| Biphenyl SCHEMBL11241682 | 0.86 | ALDH1A1 (0.61) | ALDH1A1SLC18A3EPHX1HIF1A | |
| Biphenyl SCHEMBL1609089 | 0.86 | ALDH1A1 (0.61) | ALDH1A1SLC18A3EPHX1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409468-B9 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1409468-B1 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| US-6995269-B2 | Guanidinobenzamides | CHIRON CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1409468-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6638927-B2 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl) -ethyl)-benzamide for example | CHIRON CORPORATION | 2003-10-28 | — | — | US | disclosed |
| US-20030199499-A1 | Novel guanidinobenzamides | CHIRON CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| WO-2002018327-A2 | GUANIDINOBENZAMIDES AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199499-A1 | Novel guanidinobenzamides | GUCY1B2, GPR119, GUCY1B1 | ALDH1A1 1371/4885HSD11B1 2267/4885CES2 195/4885 |
| US-20020137939-A1 | Melanocortin-4 receptor (MC4-R) agonists; treating obesity or diabetes; 4-((N-cyclohexyl-3,5-dimethyl-piperazine-1-carboximidoyl)-amino)-N-(2-(2,4 -dichlorophenyl)-ethyl)-benzamide for example | MC4R, MC5R, MC3R | ALDH1A1 2079/4885HSD11B1 2772/4885CES2 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.